5.45
-0.14(-2.50%)
Currency In USD
Address
33 Broadwick Street
London, W1F 0DQ
United Kingdom of Great Britain and Northern Ireland
Phone
44 64 6905 3974
Website
Sector
Healthcare
Industry
Medical - Care Facilities
Employees
166
First IPO Date
September 18, 2020
| Name | Title | Pay | Year Born |
| Mr. Kabir Kumar Nath M.A., M.B.A. | Chief Executive Officer & Director | 931,682 | 1964 |
| Dr. Guy Goodwin | Chief Medical Officer | 573,231 | 1948 |
| Ms. Teri Loxam M.B.A. | Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer | 674,634 | 1973 |
| Dr. Susan C. Stansfield Ph.D. | Advisor | 0 | N/A |
| Dr. Greg Ryslik Ph.D. | Chief Technology Officer | 0 | N/A |
| Ms. Lori Englebert M.B.A. | Chief Commercial Officer | 0 | 1979 |
| Dr. Michael Gold M.D., M.Sc. | Chief Research & Development Officer | 0 | 1961 |
| Mr. Lars Christian Wilde | Senior Advisor | 0 | 1986 |
| Mr. Stephen D. Schultz | Senior Vice President of Investor Relations | 0 | N/A |
| Ms. Anne Benedict | Chief People Officer | 0 | N/A |
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.